Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 22, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...
Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer
July 12, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
June 22, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
Enrollment stopped in RELIANT trialAntitumor activity observed in heavily pretreated patients with metastatic pancreatic cancer, including those previously treated with nab-paclitaxel; addition of...
Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
June 15, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors
June 10, 2021 07:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
May 06, 2021 16:10 ET
|
Corcept Therapeutics Incorporated
In a 178-patient, controlled, Phase 2 trial, women with platinum-resistant ovarian cancer who received relacorilant plus nab-paclitaxel experienced improved progression free survival (PFS) compared to...
Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)
May 06, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer
May 06, 2021 16:01 ET
|
Corcept Therapeutics Incorporated
Women with platinum resistant ovarian cancer experienced longer progression free survival with relacorilant plus nab-paclitaxel than with nab-paclitaxel aloneWomen who received a higher dose of...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 29, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update...